newsfilter
← Latest News
PR Newswire·

Azitra, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference

AZTR
  • Azitra, Inc. (NYSE American: AZTR) announced that Co-founder & Chief Operating Officer Travis Whitfill, Ph.D., MPH, will deliver a virtual presentation at the H.C. Wainwright 28th Annual Global Investment Conference.
  • The conference is scheduled to take place from September 14-16, 2026, in New York City.
  • Dr. Whitfill will provide an update on the ATR-COSF program, detailing initial data on leveraging microbial genetic engineering for cosmetic applications targeting fine lines & wrinkles.
  • The presentation will also cover continued enrollment in the first cohort of the Phase 1/2 clinical trial evaluating ATR-04 for EGFR inhibitor-associated rash.
  • Dr. Whitfill will conduct one-on-one meetings with registered investors & potential partners to discuss the company's business strategy, recent achievements, & anticipated milestones.
  • Azitra holds Fast Track designation from the FDA for ATR-04, a live biotherapeutic for EGFR inhibitor-associated rash impacting approximately 150,000 people in the U.S.
  • The company's portfolio includes ATR-COSF, a recombinant protein technology for skincare, & ATR-04, alongside additional recombinant protein initiatives for biotechnology research & manufacturing.
  • Azitra utilizes a technology platform combining engineered proteins, topical live biotherapeutics, artificial intelligence, & a proprietary microbial library.
  • The press release contains forward-looking statements regarding expected timing for safety data, topline results, & clinical trials for ATR-12, ATR-04, & ATR-COSF.
  • Contact information for the company includes Norman Staskey (CFO), Tiberend Strategic Advisors (Investor Relations), & Tiberend Strategic Advisors (Media Relations).